PhRMA: More than 1650 clinical trials are underway for COVID-19 treatments and vaccines

The biopharmaceutical industry is working around the world on ways to overcome COVID-19.
currently worldwide, there are 1,684 clinical trials under way for the treatment of COVID-19 and vaccine development, including 560 treatment options for COVID-19 and related complications.
, biopharmaceutical companies are pushing ahead with research into the COVID-19 vaccine.
that more than 40 vaccine candidates have been tested in clinical trials.
of the American Association of Pharmaceutical Research and Manufacturers (PhRMA) is dedicated to finding solutions to diagnose, treat and prevent COVID-19.
Over the past few decades, PhRMA member companies have invested billions of dollars in building advanced manufacturing facilities and developing key cutting-edge technologies, enabling the industry to accelerate vaccine development, identify and rapidly roll out promising treatments, and rapidly produce new vaccines and develop new treatments for patients.
30 October 2020, there are 1,560 clinical trials of potential treatments and vaccines under way, and 124 clinical trials of COVID-19 vaccines.
, most clinical trials are conducted simultaneously in different countries.
data from the U.S. Clinical Trials Database, the Global Drug Research and Development Information Database, and the World Health Organization's International Clinical Trials Registration Platform.
results from a summary analysis.
data as of October 30, 2020, 560 treatment options for COVID-19 and related complications are in clinical trials worldwide.
: Some drugs may be divided into two different stages of development.
150 of these treatments are involved from PhRMA member companies.
of these ongoing clinical trials are directed at the treatment of COVID-19 itself, while the other half are directed at complications such as pneumonia caused by COVID-19.
note that more than 990 clinical trial drugs have previously been approved for use in other adaptations, such as some antiviral compositions, and 233 clinical trial drugs are new compounds developed specifically for the treatment of COVID-19.
."The World Health Organization's International Clinical Trials Registration Platform, as detailed in the biopharmaceutical industry has made significant progress in developing potential vaccines, although COVID-19 was only identified in December 2019.
Currently, there are 124 clinical trials for 44 candidate vaccines, of which 34 are in clinical phase I and II, and 10 candidate vaccines have entered clinical phase III trials involving more than 100,000 patients.
production and transportation biopharmaceutical researchers are also exploring the best methods for the production of safe and effective therapeutic drugs and vaccines.
the transfer process from the laboratory to the production facility is complex and must take into account the safety and effectiveness of the vaccine components.
to speed up the deployment of vaccines, despite the potential economic risks, many companies will start the production process before coVID-19 vaccines are regulatoryly approved for market.
challenging task of how to safely deliver hundreds of millions of doses of vaccines to patients around the world.
require special transport and storage conditions, such as temperature control.
this end, the biopharmaceutical industry is working closely with different local governments and non-governmental organizations, including the Global Access mechanism for new crown vaccines (Covax), the Wellcome Trust and the Gates Foundation, to lay the foundation for a successful distribution of vaccines worldwide in the future.
PhRMA will continue to follow the latest developments in COVID-19.
for the latest research and development data, please visit PhRMA's official website: https://phrma.org/coronavirus/activity-tracker.